Catálogo de publicaciones - revistas

<jats:p>More patients and the rising costs of new cancer treatments spark debate over how much is too much—and who should decide.</jats:p>

<jats:p>Cancer and other chronic diseases have received little attention from global health advocates. That's beginning to change.</jats:p>

<jats:p>Felicia Knaul, a health economist at Harvard Medical School in Boston, is one half of a Mexican-Canadian power couple that aims to end the neglect of cancer as a disease of the poor—and will succeed, if anyone can, say colleagues.</jats:p>

<jats:p>Cancer researchers are trying to harness siblings of p53, the famous tumor-blocking protein.</jats:p>

<jats:p>The description and interpretation of genomic abnormalities in cancer cells have been at the heart of cancer research for more than a century. With exhaustive sequencing of cancer genomes across a wide range of human tumors well under way, we are now entering the end game of this mission. In the forthcoming decade, essentially complete catalogs of somatic mutations will be generated for tens of thousands of human cancers. Here, I provide an overview of what these efforts have revealed to date about the origin and behavioral features of cancer cells and how this genomic information is being exploited to improve diagnosis and therapy of the disease.</jats:p>

<jats:p>Metastasis causes most cancer deaths, yet this process remains one of the most enigmatic aspects of the disease. Building on new mechanistic insights emerging from recent research, we offer our perspective on the metastatic process and reflect on possible paths of future exploration. We suggest that metastasis can be portrayed as a two-phase process: The first phase involves the physical translocation of a cancer cell to a distant organ, whereas the second encompasses the ability of the cancer cell to develop into a metastatic lesion at that distant site. Although much remains to be learned about the second phase, we feel that an understanding of the first phase is now within sight, due in part to a better understanding of how cancer cell behavior can be modified by a cell-biological program called the epithelial-to-mesenchymal transition.</jats:p>

<jats:p>Understanding how the immune system affects cancer development and progression has been one of the most challenging questions in immunology. Research over the past two decades has helped explain why the answer to this question has evaded us for so long. We now appreciate that the immune system plays a dual role in cancer: It can not only suppress tumor growth by destroying cancer cells or inhibiting their outgrowth but also promote tumor progression either by selecting for tumor cells that are more fit to survive in an immunocompetent host or by establishing conditions within the tumor microenvironment that facilitate tumor outgrowth. Here, we discuss a unifying conceptual framework called “cancer immunoediting,” which integrates the immune system’s dual host-protective and tumor-promoting roles.</jats:p>

<jats:p>A Tudor domain protein mediates posttranscriptional control of gene expression and is required for eye-lens development.</jats:p>

<jats:p>The Suzaku satellite provides a census of the gas, metals, and dark matter out to the outskirts of the Perseus Cluster.</jats:p>

<jats:p>Three techniques are used to probe the pseudogap state of cuprate high-temperature superconductors.</jats:p>